Safety Outcomes and Near-Adult Height Gain of Growth Hormone-Treated Children with SHOX Deficiency: Data from an Observational Study and a Clinical Trial

Imane Benabbad\textsuperscript{a} Myriam Rosilio\textsuperscript{a} Christopher J. Child\textsuperscript{b} Jean-Claude Carel\textsuperscript{c} Judith L. Ross\textsuperscript{d,e} Cheri L. Deall\textsuperscript{f} Stenvert L.S. Drop\textsuperscript{g} Alan G. Zimmermann\textsuperscript{h} Nan Jia\textsuperscript{h} Charmian A. Quigley\textsuperscript{i} Werner F. Blum\textsuperscript{j}

\textsuperscript{a}Endocrinology and Diabetes Unit, Eli Lilly, Neuilly-sur-Seine, France; \textsuperscript{b}Lilly Research Laboratories, Windlesham, UK; \textsuperscript{c}Department of Pediatric Endocrinology and Diabetology, and INSERM U690, University Paris 7, Denis Diderot, Hôpital Robert Debé, Paris, France; \textsuperscript{d}Department of Pediatrics, Thomas Jefferson University, Philadelphia, PA, and \textsuperscript{e}DuPont Hospital for Children, Wilmington, DE, USA; \textsuperscript{f}University of Montreal and CHU Ste-Justine, Montreal, QC, Canada; \textsuperscript{g}Department of Pediatrics, Erasmus Medical Centre Sophia, Rotterdam, The Netherlands; \textsuperscript{h}Global Statistical Sciences, Eli Lilly and Company, and \textsuperscript{i}Indiana University School of Medicine, Indianapolis, IN, USA; \textsuperscript{j}University Children’s Hospital, University of Giessen, Giessen, Germany

**Key Words**

SHOX deficiency · Growth hormone treatment · Short stature · Growth · Safety · Near-adult height

**Abstract**

**Background/Aims:** To assess auxological and safety data for growth hormone (GH)-treated children with SHOX deficiency.

**Methods:** Data were examined for GH-treated SHOX-deficient children (n = 521) from the observational Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS). For patients with near-adult height information, GeNeSIS results (n = 90) were compared with a clinical trial (n = 28) of SHOX-deficient patients. Near-adult height was expressed as standard deviation score (SDS) for chronological age, potentially increasing the observed effect of treatment. **Results:** Most SHOX-deficient patients in GeNeSIS had diagnoses of Leri-Weill syndrome (n = 292) or non-syndromic short stature (n = 228). For GeNeSIS patients with near-adult height data, mean age at GH treatment start was 11.0 years, treatment duration 4.4 years, and height SDS gain 0.83 (95% confidence interval 0.49–1.17). Respective ages, GH treatment durations and height SDS gains for GeNeSIS patients prepubertal at baseline (n = 42) were 9.2 years, 6.0 years and 1.19 (0.76–1.62), and for the clinical trial cohort they were 9.2 years, 6.0 years and 1.25 (0.92–1.58). No new GH-related safety concerns were identified.

**Conclusion:** Patients with SHOX deficiency who had started GH treatment before puberty in routine clinical practice had a similar height gain to that of patients in the clinical trial on which approval for the indication was based, with no new safety concerns.

© 2016 The Author(s)
Published by S. Karger AG, Basel

**Introduction**

Growth is influenced by many factors, both genetic and environmental, and short stature is a frequent reason for referral to a paediatric endocrinologist. One of the
Outcomes of GH-Treated Children with SHOX Deficiency

many genes involved in statural growth is the short stature homeobox-containing (SHOX) gene located in the pseudoautosomal region (PAR1) of the X and Y chromosomes [1, 2]. This gene may be affected by mutations and deletions in the coding region and in the enhancer regions [1–5]. Deficiency of the gene product results in a broad spectrum of phenotypic characteristics, including variable degrees of impaired growth [2, 6–8]. In addition to short stature, children with SHOX deficiency may also have skeletal anomalies consistent with mesomelic skeletal dysplasia, including short forearms and lower legs, and bowing of the forearms [2, 7–10]. Such clinical signs are typical of Leri-Weill syndrome (LWS); however, some children with SHOX deficiency may have no evidence of skeletal dysplasia, identifiable clinical anomalies, or other definable causes for their short stature [8–10].

Girls and women with Turner syndrome lack all or part of the second sex chromosome and, therefore, have only one copy of SHOX; this haploinsufficiency underlies a substantial portion of the short stature seen in patients with Turner syndrome [11]. Many studies have demonstrated increased adult height following growth hormone (GH) therapy in patients with Turner syndrome [12–16]. For this reason, GH therapy was examined in patients with non-Turner syndrome SHOX deficiency, and several studies have now shown that GH can have a positive effect on the growth of SHOX-deficient patients [16–19].

Approval for the indication of GH treatment of short stature due to SHOX deficiency was based on data from the 2-year randomised treatment phase of a single clinical trial [17]. After completion of this randomised phase, all participants were offered GH therapy until attainment of near-adult (final) height [16]. It is important to determine whether results from clinical trials are matched by subsequent outcomes in routine clinical practice. Observational programmes, such as the Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS), are carried out to assess safety and effectiveness outcomes of children with growth disorders, with or without GH treatment. The present study aimed to analyse GeNeSIS data for patients with short stature associated with SHOX deficiency and to evaluate long-term effects of GH therapy on safety and near-adult height. Results for patients who achieved near-adult height during this observational study were assessed in relation to results from the previously published clinical trial of GH-treated SHOX-deficient patients [16, 17].
cluded the investigator-defined diagnosis of the cause of short stature, previous laboratory data and pre-existing medications. Baseline clinical variables included height, weight, parental heights (for the calculation of the genetic target height [sex-adjusted average of parental heights]) and bone age. Pubertal stage was evaluated according to the Tanner classification. Height, weight and pubertal stage were documented at follow-up visits.

Baseline data in the clinical trial included medical history, height, weight, parental heights and bone age. All patients had SHOX deficiency confirmed by centralised genetic analysis of the SHOX gene [8]. Investigators also reported the clinical phenotype, with categorisation as either having LWS or non-syndromic short stature. At the start of GH therapy, all patients were prepubertal (Tanner stage 1), had no evidence of GH deficiency or resistance and were not taking any growth-influencing medications. Height, weight and pubertal development changes were evaluated at follow-up visits.

Patients from GeNeSIS and the clinical trial were considered to have reached near-adult height (final height) during follow-up if they attained one of the following criteria: height velocity < 2 cm/year, X-ray of the hand showing closed epiphyses or bone age > 14 years for girls or > 16 years for boys. Bone age was assessed from radiographs of the left hand and wrist, which were read using Greulich and Pyle standards [20].

The clinical trial predominantly enrolled patients from central European countries; therefore, standard deviation scores (SDS) for height were calculated for both GeNeSIS and the clinical trial using data from a central European reference population [21]. Near-adult height was expressed as height SDS for chronologic age at the time of the measurement, including when adult height was considered as attained, which could potentially increase the observed effect of treatment but is a well-accepted method for SDS calculation. Body mass index SDS was determined from European reference data [22].

Safety analysis for inclusion in this report was based on adverse events reported for patients who received GH therapy. Serious adverse events (SAEs) were defined as any event that resulted in death, hospitalisation, persistent or significant disability, or congenital anomaly in the offspring of a treated patient, were considered life-threatening or were significant for another reason in the opinion of the investigator. Treatment-emergent adverse events (TEAEs) were assessed for patients who had at least one follow-up visit after starting GH therapy and were defined as events that first occurred or worsened in severity. All adverse events were categorised according to the Medical Dictionary for Regulatory Authorities (MedDRA, version 11.0).

Genetic Analyses

Patients enrolled in GeNeSIS could have a diagnosis of SHOX deficiency on the basis of clinical signs, with no requirement to have a proven SHOX gene alteration, and underwent genetic testing only at the discretion of the investigator. Therefore, the molecular technique varied according to the laboratory carrying out the genetic testing. In France, the analyses were carried out by the Necker-Enfants Malades hospital group, Paris, as previously described [23]. Samples from other European countries were mainly analysed at Bioscientia, Germany, although some were analysed at other local laboratories; samples from US sites were analysed at Esoterix Endocrinology, Calabasas Hills, CA, USA. Analysis of the downstream and upstream enhancer regions for the SHOX gene was carried out for a limited number of patients who had entered GeNeSIS more recently.

In the clinical trial, all patients were required to have a demonstrated SHOX gene alteration, based on central laboratory analysis [8]. The enhancer domains for the SHOX gene had not been identified at the time of screening for the clinical trial and were, therefore, not analysed.

Statistics

Data for patients with SHOX deficiency in GeNeSIS were analysed using descriptive statistics. Results for continuous variables are presented as means ± SD with 95% confidence intervals (CIs). Information on categorical variables is presented as number of patients and percentage of the relevant total population. Safety data were assessed for all patients who received GH treatment in both GeNeSIS and the clinical trial. Near-adult heights were assessed using mean and 95% CI of height SDS for age at the time of measurement.

Results

Baseline Data for Patients with SHOX Deficiency in GeNeSIS

At the March 2014 data lock for this report, the GeNeSIS database contained evaluable information for 21,577 GH-treated paediatric patients, including 521 patients (314 female, 207 male) with a diagnosis of SHOX deficiency enrolled between 2000 and 2013. The majority of the GH-treated SHOX-deficient patients were from Germany (n = 197) and France (n = 180), followed by the USA (n = 61), Spain (n = 25) and Czech Republic (n = 20), with the remainder spread among 11 other countries.

Among the 521 patients, the numbers with an investigator-provided diagnosis of either LWS (56%) or non-syndromic short stature (44%) are shown in Figure 1, together with available information on identified gene defects. Molecular alterations affecting the SHOX gene, as described by the investigator, were reported for 207 (71%) of the 292 patients with a diagnosis of LWS. Of these, 194 patients (66%) had a reported molecular alteration encompassing the SHOX gene, with or without a reported alteration in the PAR1, and 12 (4%) had identified alterations in the regulatory regions of the SHOX gene only; the nature of the genetic alteration was not specified for 1 patient. The majority of the SHOX alterations were complete or partial deletions involving the coding region (153/207 = 74%), 16% were nonsense or nonsense mutations and 1% were partial duplications. No alteration of the SHOX gene or PAR1 was identified for 54 (18%) of the patients with LWS phenotype. Of the 228 patients with non-syndromic SHOX deficiency, alterations in the SHOX gene were identified in 218, comprising deletions.
for 124 (57%), mutations for 67 (31%), and other variations for 27 (12%).

Baseline characteristics of all patients with SHOX deficiency in GeNeSIS are summarised in Table 1. Mean age at the start of GH treatment was 9.4 ± 3.2 (95% CI 9.1–9.6) years. Mean height SDS was −3.01 ± 0.77 (95% CI −3.08 to −2.94), and mean initial GH dose was 0.30 ± 0.09 (95% CI 0.29–0.31) mg/kg/week.

Safety Information

For 514 patients with SHOX deficiency in GeNeSIS, with available information, mean duration of follow-up was 2.8 ± 2.0 years. One death was reported and 3 patients discontinued due to adverse events. In the clinical trial, 49 patients received GH for a mean duration of 7.0 ± 1.8 years for those initially randomised to GH (n = 26) and 4.8 ± 2.0 years for those randomised to be untreated with GH for the first 2 years (n = 23); there were no reported deaths or discontinuations due to adverse events.

In GeNeSIS, 14 SAEs were reported for 12 patients (appendicitis [n = 2], chronic renal failure [n = 2], adenoidectomy, death, hypertension, ligament injury, limb operation, lower limb fracture, neoplasms recurrence, osteomyelitis, post-streptococcal glomerulonephritis, and spondylolisthesis). The SAE reported as death was a girl diagnosed with LWS, with no identified SHOX gene defect; she received a kidney transplant following chronic renal failure, had received GH for approximately 2 years and 4 months, and died 18 months after discontinuing GH. The neoplasm recurrence was a relapse of pilocytic astrocytoma.
astrocytoma approximately 1 year and 11 months after GH initiation.

In the clinical trial, 10 SAEs were reported for 6 patients (epilepsy \(n = 2\), abdominal pain, acute seizure, appendicitis, arthritis, Crohn disease, inguinal hernia, tonsillar hypertrophy, and vomiting). The 2 epilepsy events and the acute seizure all occurred in 1 patient. No TEAEs were reported for 397 (80%) of the 495 patients with SHOX deficiency in GeNeSIS who had at least one follow-up visit after starting GH therapy. A TEAE was reported for 49 patients (20%); the most frequent were precocious puberty and arthralgia (Table 2). For the 49 patients in the clinical trial, 43 (87.8%) reported at least 1 TEAE; the majority were for common childhood illnesses, particularly infections and infestations reported for 32 patients (65%). Scoliosis was reported for 5 (10%) patients in the clinical trial and 2 (0.4%) patients in GeNeSIS. There were no reports of diabetes mellitus in the GH-treated patients with SHOX deficiency in either study.

Near-Adult Height Data

Near-adult height data were available at the time of analysis for 90 GH-treated patients with SHOX deficiency in GeNeSIS, 42 of whom were prepubertal at baseline; near-adult height data were available for 28 patients in the clinical trial, all of whom were prepubertal at baseline.

<table>
<thead>
<tr>
<th>Table 1. Characteristics at the start and height gain after 1 year of GH treatment of patients with SHOX deficiency in the GeNeSIS observational programme</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Children with SHOX deficiency ((n=521))</strong></td>
</tr>
<tr>
<td>Female/male (314 (60.3)/207 (39.7))</td>
</tr>
<tr>
<td>Tanner stage 1 (female/male), % (69.0/83.6)</td>
</tr>
<tr>
<td>Age, years (9.4 \pm 3.2 (9.1 to 9.6))</td>
</tr>
<tr>
<td>Bone age delay, years (-0.9 \pm 1.2 (-1.1 to -0.8))</td>
</tr>
<tr>
<td>Height SDS (-3.01 \pm 0.77 (-3.08 to -2.94))</td>
</tr>
<tr>
<td>Target height SDS (-1.14 \pm 0.93 (-1.23 to -1.06))</td>
</tr>
<tr>
<td>Height SDS – target height SDS (-1.87 \pm 1.05 (-1.96 to -1.77))</td>
</tr>
<tr>
<td>GH dose, mg/kg/week (0.30 \pm 0.09 (0.29 to 0.31))</td>
</tr>
<tr>
<td>First year gain in height SDS (0.53 \pm 0.51 (0.47 to 0.59))</td>
</tr>
</tbody>
</table>

Data show number of patients (% of total) or mean ± SD (95% CI). CI, confidence interval; SD, standard deviation; SDS, standard deviation score; SHOX, short stature homeobox-containing gene.

Table 2. Reported SAEs and TEAEs during GH treatment of patients with SHOX deficiency in GeNeSIS and the clinical trial

<table>
<thead>
<tr>
<th>Number of GH-treated patients</th>
<th>GeNeSIS</th>
<th>Clinical trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of GH-treated patients with ≥1 SAE</td>
<td>12 (2.3%)</td>
<td>6 (12.2%)</td>
</tr>
<tr>
<td>Number of GH-treated patients with follow-up</td>
<td>495</td>
<td>49</td>
</tr>
<tr>
<td>Patients with ≥1 TEAE</td>
<td>98 (19.8%)</td>
<td>43 (87.8%)</td>
</tr>
</tbody>
</table>

**TEAEs reported most frequently:**
- Precocious puberty: 13 (2.6%) / 1 (2.0%)
- Arthralgia: 12 (2.4%) / 6 (12.2%)
- Headache: 8 (1.6%) / 9 (18.4%)
- Hypothyroidism: 6 (1.2%) / 1 (2.0%)
- Back pain: 5 (1.2%) / 6 (12.2%)
- Madelung deformity: 2 (0.4%) / 8 (16.3%)
- Nasopharyngitis: 1 (0.2%) / 7 (14.3%)
- Ear infection: 1 (0.2%) / 6 (12.2%)
- Cough: 1 (0.2%) / 6 (12.2%)
- Congenital bowing of long bones: 0 / 9 (18.4%)
- Vomiting: 0 / 6 (12.2%)

GH, growth hormone; SAE, serious adverse event; SHOX, short stature homeobox-containing gene; TEAE, treatment-emergent adverse event.

* MedDRA preferred terms; events reported in >1% of patients in GeNeSIS or >12% of clinical trial patients.* MedDRA preferred term states congenital, reflecting the initial clinical observation of Madelung deformity during study participation.

The genotype and phenotype data for these patients are shown in Table 3. In both GeNeSIS and the clinical trial, the majority of patients with available near-adult height data had a diagnosis of LWS. For patients in GeNeSIS with genetic data available, the proportions with an identified mutation, deletion or duplication were very similar to the proportions identified during screening for the clinical trial (Table 3).

Patient characteristics, auxological parameters and GH treatment details at GH initiation and near-adult height are summarised in Table 4. The mean age at GH start was greater for the full group of 90 patients with near-adult height data in GeNeSIS than for the patients in the clinical trial; however, the mean age of the 42 prepubertal patients in this subgroup of GeNeSIS was similar to that of the patients in the clinical trial (Table 4). Mean age at near-adult height for both the full group and the prepubertal subgroup of patients in GeNeSIS was similar to that of the patients in the clinical trial. Thus, mean treatment duration was shorter for the complete GeNeSIS cohort with near-adult height data than for patients in the
clinical trial, whereas GeNeSIS patients who started GH when prepubertal had a treatment duration similar to that of patients in the clinical trial. Initial and last reported doses of GH were lower for the full cohort of GeNeSIS patients with near-adult height data than for patients in the clinical trial. For the GeNeSIS patients who were prepubertal at the GH start, the initial GH dose was similar to that for the patients in the clinical trial, but the last reported dose was lower.

Height SDS at baseline and near-adult height, as well as change in height SDS are shown in Figure 2. Mean change in height SDS from GH start to near-adult height was 0.83 (95% CI 0.49–1.17) for the full GeNeSIS cohort and 1.19 (95% CI 0.76–1.62) for the prepubertal subgroup in GeNeSIS, compared with 1.25 (95% CI 0.92–1.58) for patients in the clinical trial. At the time of near-adult height measurement, 53% of the patients in GeNeSIS and 57% of the patients in the clinical trial had height above the lower limit of the normal range (>–2 SDS).

Table 3. Phenotype and genotype information for patients with SHOX deficiency for whom near-adult height data were reported at the time of analysis

<table>
<thead>
<tr>
<th></th>
<th>GeNeSIS (n = 90)</th>
<th>Clinical trial (n = 28)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Phenotype</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leri-Weill syndrome</td>
<td>56 (62%)</td>
<td>17 (61%)</td>
</tr>
<tr>
<td>Non-syndromic short stature</td>
<td>34 (38%)</td>
<td>11 (39%)</td>
</tr>
<tr>
<td><strong>Genotype</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deletion</td>
<td>43 (48%) [77%]</td>
<td>22 (79%)</td>
</tr>
<tr>
<td>Mutation</td>
<td>9 (10%) [16%]</td>
<td>5 (18%)</td>
</tr>
<tr>
<td>Translocation</td>
<td>1 (1%) [2%]</td>
<td>0</td>
</tr>
<tr>
<td>Duplication</td>
<td>1 (1%) [2%]</td>
<td>1 (4%)</td>
</tr>
<tr>
<td>Regulatory region alteration</td>
<td>2 (2%)</td>
<td>4%</td>
</tr>
<tr>
<td>No identified alteration/no test</td>
<td>34 (38%)</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Data show numbers of patients with phenotype/genotype (percentage of total number of patients for whom near-adult height was reported) [percentage of the 56 GeNeSIS patients with identified genetic alteration for whom near-adult height was reported]. Assignments of genetic alterations were based on the available reported data and reflect the classification of individual patients by their clinician. N/A, not applicable; SHOX, short stature homeobox-containing gene.

Discussion

Among patients enrolled in the GeNeSIS observational study and treated with GH in routine clinical practice, a diagnosis of SHOX deficiency was reported by physicians for 521 patients. For 56% of these patients the diagnosis was reported as LWS, and for 44% the phenotype was reported to be “non-syndromic” SHOX deficiency (also known as “idiopathic” short stature). This phenotype distribution was similar to the approximately equal proportions of LWS versus idiopathic short stature for the total cohort included in the clinical trial [17]. There was also 1 GH-treated patient in GeNeSIS with a diagnosis of Langer mesomelic dysplasia, the homozygous form of SHOX deficiency; although GH treatment may have limited effectiveness in promoting height gain in patients with this condition, the patient was included in the analysis in reflection of the real-world nature of data from an observational study. All of the patients with SHOX deficiency had severe growth impairment at baseline, and GH treatment for 1 year was associated with a mean height SDS gain of 0.53.

The genetic information in GeNeSIS was as provided by the investigators, with different analysis techniques used over a long enrolment period. However, the data showed that the majority of the genetic alterations for patients in GeNeSIS were complete or partial deletions of the SHOX gene. Consistent with previous reports, enrolled patients more commonly had deletions of the

Fig. 2. Height standard deviation score at the start of growth hormone treatment and at near-adult height, with change from baseline to near-adult height, for patients who attained near-adult height during GeNeSIS follow-up, patients who were prepubertal (Tanner 1) and reached near-adult height during GeNeSIS, and those who reached near-adult height in the clinical trial [16]. Bars show means with 95% confidence intervals; dashed line indicates lower limit of normal height range. SDS, standard deviation score.
SHOX gene than single base mutations [2, 24, 25]. Prevalence of deletions versus point mutations was greater in the patients with LWS phenotype than in those with the non-syndromic phenotype, suggesting that the phenotype may correlate to some extent with the magnitude of the genetic alteration. Alterations in the SHOX regulatory region were only found in 5–6% of the patients with LWS and non-syndromic SHOX deficiency (18% of patients with LWS and 9% of those with non-syndromic SHOX deficiency had deletions that also extended to other parts of PAR1, potentially including regulatory elements). The relatively small number of patients in GeNeSIS with identifiable alterations in the regulatory regions of the SHOX gene [26, 27] is most likely due to the fact that, during the enrolment period from 1999 to 2013, screening for alterations in enhancer elements was not uniformly performed in genetic laboratories [6, 8, 25, 28].

Analysis of the GeNeSIS patients known to be prepubertal at GH initiation showed that they had a similar mean height SDS gain from the start of GH treatment to that seen for the patients in the clinical trial. In both cohorts, substantial mean height SDS gains of approximately 1.2 (equivalent to approximately 8 cm) were observed. Apart from the previous report of the clinical trial, the only other study to date that has reported final height/near-adult height data for GH-treated patients with SHOX deficiency found a mean height SDS gain of 0.6 in a group of 5 peripubertal patients who were treated with a gonadotropin-releasing hormone analogue for pubertal suppression and started GH at a mean age of 11.6 years [29]. These findings suggest that, similar to other short stature indications for GH treatment, height gain is greater when GH is initiated early, particularly before onset of puberty [30, 31]. However, the use of height SDS for chronological age of the near-adult height measurement in children with a mean age of 15.7 years may not accurately measure the true adult height SDS.

Identification of patients with potential SHOX deficiency when prepubertal can be challenging, especially in boys, because most young children with SHOX deficiency lack specific clinical signs such as high-arched palate or Madelung deformity [32, 33]. Careful measurement of body proportions can elicit more subtle markers of SHOX deficiency, such as increased sitting height-to-height ratio and reduced extremities-to-trunk ratio [32, 34]. Furthermore, meticulous examination of the parents for Madelung deformity, complemented by forearm X-rays of the child, can facilitate an earlier diagnosis of SHOX deficiency in a prepubertal child with non-syndromic short stature [2].

The phenotypes and genotypes were very similar for the prepubertal patients with SHOX deficiency in GeNeSIS and the patients in the clinical trial. Thus, the similar height gains observed for the prepubertal GeNeSIS and clinical trial cohorts would indicate that the clinical trial data on which the relevant approval was based are reasonably generalisable to that of patients with SHOX deficiency in routine clinical practice, when GH is initiated before the start of puberty.

### Table 4. Demographics, auxology and GH treatment profile at baseline (GH initiation) and at near-adult height for all patients in GeNeSIS, the subgroup of patients in GeNeSIS who were prepubertal (Tanner stage 1) at GH start, and patients in the clinical trial, for whom NAH was attained during follow-up

<table>
<thead>
<tr>
<th></th>
<th>GeNeSIS</th>
<th>Prepubertal (n = 42)</th>
<th>Clinical Trial (n = 28)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Female, n (%)</strong></td>
<td>59 (65.6)</td>
<td>32 (76.2)</td>
<td>15 (53.6)</td>
</tr>
<tr>
<td><strong>Age at GH initiation, years</strong></td>
<td>11.0 ± 2.4 (10.5 to 11.5)</td>
<td>9.2 ± 2.2 (8.6 to 9.9)</td>
<td>9.2 ± 2.4 (8.3 to 10.2)</td>
</tr>
<tr>
<td><strong>Age at NAH, years</strong></td>
<td>15.7 ± 1.4 (15.4 to 16.0)</td>
<td>15.5 ± 1.3 (15.1 to 15.9)</td>
<td>15.5 ± 1.3 (15.0 to 16.0)</td>
</tr>
<tr>
<td><strong>Bone age delay at baseline, years</strong></td>
<td>-0.6 ± 1.5 (-1.0 to -0.2)</td>
<td>-0.9 ± 1.6 (-1.5 to -0.3)</td>
<td>-0.9 ± 0.7 (-1.2 to -0.7)</td>
</tr>
<tr>
<td><strong>Height SDS at baseline</strong></td>
<td>-3.01 ± 0.87 (-3.19 to -2.83)</td>
<td>-3.20 ± 0.88 (-3.48 to -2.93)</td>
<td>-3.20 ± 0.77 (-3.50 to -2.90)</td>
</tr>
<tr>
<td><strong>Target height SDS</strong></td>
<td>-1.14 ± 0.89 (-1.33 to -0.95)</td>
<td>-1.21 ± 0.77 (-1.46 to -0.97)</td>
<td>1.6 ± 0.9 (-1.92 to -1.19)</td>
</tr>
<tr>
<td><strong>NAH SDS – target height SDS</strong></td>
<td>-0.96 ± 1.41 (-1.28 to -0.64)</td>
<td>-0.78 ± 1.21 (-1.18 to -0.38)</td>
<td>NA</td>
</tr>
<tr>
<td><strong>GH dose at start, mg/kg/week</strong></td>
<td>0.32 ± 0.10 (0.30 to 0.34)</td>
<td>0.34 ± 0.08 (0.31 to 0.37)</td>
<td>0.36 ± 0.02 (0.35 to 0.37)</td>
</tr>
<tr>
<td><strong>GH dose last reported, mg/kg/week</strong></td>
<td>0.33 ± 0.10 (0.30 to 0.35)</td>
<td>0.33 ± 0.10 (0.30 to 0.36)</td>
<td>0.38 ± 0.02 (0.37 to 0.38)</td>
</tr>
<tr>
<td><strong>Treatment duration, years</strong></td>
<td>4.40 ± 2.33 (3.91 to 4.90)</td>
<td>5.98 ± 2.15 (5.31 to 6.65)</td>
<td>6.02 ± 2.01 (5.24 to 6.79)</td>
</tr>
</tbody>
</table>

Data show mean ± SD (95% CI). CI, confidence interval; GH, growth hormone; NA, not available; NAH, near-adult height; SD, standard deviation; SDS, standard deviation score; SHOX, short stature homeobox-containing gene.
Analysis of safety information from the GH-treated patients with SHOX deficiency in GeNeSIS did not indicate any new concerns. The proportion of patients for whom at least 1 TEAE was reported was substantially greater in the clinical trial than in GeNeSIS; this was not unexpected because adverse event reporting was mandated in the clinical trial, whereas patients and investigators are less likely to report adverse events during routine clinical management and treatment. There was no evidence for excessive bone maturation or any worsening of dysmorphic or skeletal features. Scoliosis was reported at a low incidence: 5 cases in the clinical trial, of which 1 was considered by the investigators to be possibly related to GH treatment, and 2 cases reported in the GeNeSIS population, both of which were considered to be unrelated to GH treatment. Although precocious puberty was reported for 13 patients (2.6%) in GeNeSIS, further investigation showed that most of these cases did not meet the accepted criteria for diagnosis (i.e. breast development before 8 years of age in girls and testicular enlargement before 9 years of age in boys).

In conclusion, among patients who were treated with GH for short stature associated with SHOX deficiency in GeNeSIS, 56% had an investigator-provided diagnosis of LWS and 44% had a diagnosis of non-syndromic SHOX deficiency. These proportions for clinical phenotype of patients in routine clinical practice were similar to those for patients identified in the defining clinical trial [16]. The majority of identified alterations involving the SHOX gene were deletions, and a minority of patients had missense and nonsense mutations, duplications and translocations. Near-adult height gain for patients in GeNeSIS who were prepuberal at GH start was similar to that for patients in the clinical trial, indicating that the clinical trial results were broadly reflective of the response of patients with SHOX deficiency to GH treatment under standard clinical conditions. It remains important to identify patients with short stature due to SHOX deficiency as early as possible, because GH treatment is most effective when started at a young age.

Acknowledgements

Both GeNeSIS and the clinical trial were sponsored by Eli Lilly and Company. The authors are grateful to Valérie Cormier (InsERM U781, Paris, France) for assistance with interpretation of genetic alterations. Medical writing assistance was provided by Peter Bates (CMWS, UK) and Caroline Spencer (Rx Communications, UK) funded by Eli Lilly and Company. The authors thank all of the investigators who participated in the two studies and all of the patients and their families.

Disclosure Statement

Imane Benabbad, Myriam Rosilio, Christopher J. Child, Alan G. Zimmermann, and Nan Jia are employees and minor stockholders of Eli Lilly and Company.

Jean-Claude Carel is an investigator in clinical trials using GH sponsored by Pfizer and Eli Lilly and Company, an investigator in postmarketing studies with several brands of GH, and has received support for travel to international meetings from Ipsen and Sandoz.

Judith L. Ross has received research support from Versartis and Novo Nordisk and is a consultant for Novo Nordisk and Pfizer.

Cheri L. Deal has received grants/research support from Eli Lilly and Company, EMD Serono, Sandoz, Versartis and OPKO Health, honoraria or consultation fees from Eli Lilly and Company, EMD Serono, Sandoz, Pfizer and Roche, educational grants to support fellowship training and CME activities from Eli Lilly and Company, EMD Serono, Sandoz and Pfizer and has participated in a company-sponsored speaker’s bureau for Eli Lilly and Company, Sandoz, EMD Serono, Roche, and Novo Nordisk.

Stenvert L.S. Drop has no conflicts of interest to declare. Charmain A. Quigley and Werner F. Blum are former employees of Eli Lilly and Company. Werner F. Blum is currently a stockholder and consultant of Eli Lilly and Company.

References


DOI: 10.1159/000452973